Boji Medical Technology Co

Boji Medical Technology Co FCF Margin

The Free Cash Flow Margin of Boji Medical Technology Co (300404.SZ) as of Oct 31, 2026 is 7.86 %. In the previous year, Free Cash Flow Margin was -0.35 % — a change of -2,368.15% (higher).

FCF Margin

7.86 %

YoY

-2,368.15%

Last updated:

Free Cash Flow Margin of Boji Medical Technology Co is 2025 7.86 % . Free Cash Flow Margin of Boji Medical Technology Co was 2024 -0.35 % . It decreases by -2,368.15% higher compared to the previous year.

The Boji Medical Technology Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-6.38 CNY
Jan 1, 2019
-12.91 CNY
Jan 1, 2020
25.20 CNY
Jan 1, 2021
-7.37 CNY
Jan 1, 2022
-21.15 CNY
Jan 1, 2023
-4.72 CNY
Jan 1, 2024
-0.35 CNY
Jan 1, 2025
7.86 CNY
The Boji Medical Technology Co FCF Margin history
YEARFCF MarginYoY
7.86 %-2,368.15%
-0.35 %-92.66%
-4.72 %-77.67%
-21.15 %+187.02%
-7.37 %-129.23%
25.20 %-295.27%
-12.91 %+102.32%
-6.38 %-76.99%
-27.73 %-82.20%
-155.80 %+1,541.41%
-9.49 %-539.84%
2.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Boji Medical Technology Co Stock analysis

What does Boji Medical Technology Co do? Boji Medical Technology Co., Ltd. generates revenue through comprehensive CRO services for pharmaceutical and medical device development. The company offers preclinical research, clinical trials, data management, biostatistics, and regulatory consulting, primarily serving domestic pharmaceutical companies and research institutions. Their one-stop service model includes drug evaluation, medical device registration, and CDMO services for new drug and device production. The firm's domestic market focus ensures steady demand from local clients seeking regulatory compliance and R&D support. The company's revenue streams are derived from multiple service segments: preclinical studies, clinical research, and technology transfer. These services are tailored to meet the needs of pharmaceutical firms requiring outsourced R&D solutions. CDMO services further enhance their offerings by supporting manufacturing processes alongside development. Domestic clients form the core customer base, leveraging Boji's expertise in navigating China's regulatory landscape for drug and device approvals. Boji Medical Technology's business model centers on providing end-to-end CRO solutions, combining preclinical and clinical research with regulatory support. Their services are designed to accelerate product development cycles for clients, reducing time-to-market for new pharmaceuticals and medical devices. The firm's domestic market strategy aligns with the growing demand for R&D outsourcing within China's healthcare sector. Boji Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Boji Medical Technology Co stock

Free Cash Flow Margin of Boji Medical Technology Co is 7.86 % in 2025.

Free Cash Flow Margin of Boji Medical Technology Co changed from -0.35 % to 7.86 %, representing a -2,368.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Boji Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Boji Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Boji Medical Technology Co

All Key Metrics — Boji Medical Technology Co